Your session is about to expire
← Back to Search
JNJ-75276617 for Acute Leukemia
Study Summary
This trial is testing a new drug to find the best dose and to see if it is safe and tolerated.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with a specific type of leukemia.I agree to use a condom and not donate sperm during and 90 days after the study.I can take care of myself and am up and about more than half of my waking hours.My heart's electrical cycle length is within safe limits and I don't have a family history of Long QT syndrome.I haven't had cancer treatments like chemo or radiation in the last 4 weeks.I have an active brain or spinal cord disease.My acute leukemia has specific genetic changes.I have had a solid organ transplant.My acute leukemia has returned or is not responding to treatment, and I have no other treatment options.
- Group 1: JNJ-75276617
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals have enrolled in this clinical experiment?
"The sponsor, Janssen Research & Development, LLC is responsible for recruiting a total of 110 participants that meet the clinical trial's eligibility requirements. NYU Langone Medical Center in New york City and Cityof Hope in Duarte, California are two of many locations where patients may have access to this medical study."
What is the geographic scope of this clinical investigation?
"This clinical trial is enrolling participants at NYU Langone Medical Center in New york, City of Hope in Duarte, California and the University of California San Francisco located in San Francisco alongside many other sites."
What outcomes is this medical investigation attempting to realize?
"The trial sponsor, Janssen Research & Development LLC, has reported that the primary outcome they will be measuring over a maximal 28 day cycle is Adverse Events (AEs) as an indicator of safety and tolerability. Secondary outcomes include Plasma Concentration of JNJ-75276617, Number of Participants with Depletion of Leukemic Blasts, and Duration of Response (DOR)."
Is there capacity for additional participants in this research endeavor?
"Affirmative. Clinicaltrials.gov records reflect that this medical research, which was initially uploaded on May 19th 2021, is recruiting now. A total of 110 participants need to be enrolled from 8 distinct locations."
Has JNJ-75276617 been accepted by the FDA yet?
"JNJ-75276617 has yet to be fully tested, so our team gave it a 1 on the safety scale. This is because Phase 1 trials are not intended to demonstrate efficacy or provide adequate data regarding its security."
Share this study with friends
Copy Link
Messenger